These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

437 related items for PubMed ID: 24983187

  • 1. Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension.
    Azizi M, Perdrix L, Bobrie G, Frank M, Chatellier G, Ménard J, Plouin PF.
    J Hypertens; 2014 Oct; 32(10):2038-44; discussion 2044. PubMed ID: 24983187
    [Abstract] [Full Text] [Related]

  • 2. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study.
    Bobrie G, Frank M, Azizi M, Peyrard S, Boutouyrie P, Chatellier G, Laurent S, Menard J, Plouin PF.
    J Hypertens; 2012 Aug; 30(8):1656-64. PubMed ID: 22728905
    [Abstract] [Full Text] [Related]

  • 3. Effects of dual blockade of Renin-Angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot study.
    Grandi AM, Solbiati F, Laurita E, Maresca AM, Nicolini E, Marchesi C, Gianni M, Guasti L, Venco A.
    Am J Hypertens; 2008 Feb; 21(2):231-7. PubMed ID: 18174880
    [Abstract] [Full Text] [Related]

  • 4. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
    Cestário EDES, Fernandes LAB, Giollo-Júnior LT, Uyemura JRR, Matarucco CSS, Landim MIP, Cosenso-Martin LN, Tácito LHB, Moreno H, Vilela-Martin JF, Yugar-Toledo JC.
    Trials; 2018 Feb 12; 19(1):101. PubMed ID: 29433578
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension.
    Sato A, Suzuki Y, Saruta T.
    Hypertens Res; 1999 Mar 12; 22(1):17-22. PubMed ID: 10221346
    [Abstract] [Full Text] [Related]

  • 7. Sequential nephron blockade with combined diuretics improves diastolic function in patients with resistant hypertension.
    Fouassier D, Blanchard A, Fayol A, Bobrie G, Boutouyrie P, Azizi M, Hulot JS.
    ESC Heart Fail; 2020 Oct 12; 7(5):2561-2571. PubMed ID: 32597565
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Dual renin-angiotensin system blockade for patients with prosthesis-patient mismatch.
    Benedetto U, Melina G, Refice S, di Bartolomeo R, Roscitano A, Angeloni E, Sinatra R.
    Ann Thorac Surg; 2010 Dec 12; 90(6):1899-903; discussion 1903. PubMed ID: 21095333
    [Abstract] [Full Text] [Related]

  • 11. Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy.
    Taniguchi I, Kawai M, Date T, Yoshida S, Seki S, Taniguchi M, Shimizu M, Mochizuki S.
    Circ J; 2006 Aug 12; 70(8):995-1000. PubMed ID: 16864931
    [Abstract] [Full Text] [Related]

  • 12. Differential effects of angiotensin converting enzyme inhibition and diuretic therapy on reductions in ambulatory blood pressure, left ventricular mass, and vascular hypertrophy.
    Roman MJ, Alderman MH, Pickering TG, Pini R, Keating JO, Sealey JE, Devereux RB.
    Am J Hypertens; 1998 Apr 12; 11(4 Pt 1):387-96. PubMed ID: 9607375
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Aldosterone excess or escape: Treating resistant hypertension.
    Ubaid-Girioli S, Adriana de Souza L, Yugar-Toledo JC, Martins LC, Ferreira-Melo S, Coelho OR, Sierra C, Coca A, Pimenta E, Moreno H.
    J Clin Hypertens (Greenwich); 2009 May 12; 11(5):245-52. PubMed ID: 19534021
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Antihypertensive drug use in resistant and nonresistant hypertension and in controlled and uncontrolled resistant hypertension.
    de la Sierra A, Armario P, Oliveras A, Banegas JR, Gorostidi M, Vinyoles E, de la Cruz JJ, Segura J, Ruilope LM.
    J Hypertens; 2018 Jul 12; 36(7):1563-1570. PubMed ID: 29601411
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies.
    Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, Ford I, Cruickshank JK, Caulfield MJ, Padmanabhan S, Mackenzie IS, Salsbury J, Brown MJ, British Hypertension Society programme of Prevention And Treatment of Hypertension With Algorithm based Therapy (PATHWAY) Study Group.
    Lancet Diabetes Endocrinol; 2018 Jun 12; 6(6):464-475. PubMed ID: 29655877
    [Abstract] [Full Text] [Related]

  • 20. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L, Rutkowski P, Renke M, Larczyński W, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B.
    Am J Kidney Dis; 2008 Sep 12; 52(3):486-93. PubMed ID: 18423812
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.